Pharma AI partner map

Big pharma works with more than AI drug discovery companies. Its AI partners also include AI and cloud platforms, health data companies and research centers. The map shows the 17 pharma companies with the most AI partners, and each line is one partnership backed by dated announcements or posts.

Includes only partnerships with a public source, each linked below.

Data as of Nov 1, 2026. 17 pharma companies, 51 partnerships, 57 linked sources.

Partner map

Hover over or tab to a pharma company to see its partners. Select it to jump to its card.

Partnerships by company

Eli Lilly

6 AI partners
- Chai Discovery
  - Jan 9, 2026 Collaboration with Eli Lilly to power biologics discovery Source
- Insilico Medicine
  - Nov 11, 2025 Research and licensing collaboration with Eli Lilly valued at up to $100M Source
- insitro
  - Sep 9, 2025 Collaboration with Eli Lilly to build ML models for small molecule design on Lilly preclinical data Source
- Isomorphic Labs
  - Jan 7, 2024 Isomorphic Labs multi-target AI drug discovery collaboration Source
- NVIDIA
  - Jan 12, 2026 NVIDIA and Lilly AI co-innovation lab Source
- Profluent
  - Apr 28, 2026 Eli Lilly partnership to design recombinases for genetic medicine, valued at up to $2.25B before royalties Source
GSK

4 AI partners
- Boltz
  - Jul 2, 2026 Partnership with GSK Source
- Chai Discovery
  - Oct 9, 2026 Collaboration with GSK after GSK wet-lab evaluation found binders to all tested targets Source
- Noetik
  - Jan 8, 2026 Five-year foundation model licensing agreement with GSK for virtual cell models Source
    Aug 26, 2026 Achieved first near-term milestone in GSK collaboration Source
    Jan 8, 2026 Foundation model licensing deal with GSK (official, citing FierceBiotech) Source
- Relation Therapeutics
  - Jul 30, 2026 Expanded GSK collaboration to deploy MORGAN cellular foundation model, worth up to $110M in upfront payments and success-based milestones Source
Merck & Co.

4 AI partners
- Google Cloud
  - Apr 22, 2026 Partnership with Google Cloud on AI-enabled enterprise transformation including discovery Source
- Mayo Clinic
  - Feb 18, 2026 Mayo Clinic AI-enabled drug discovery R&D collaboration Source
- NVIDIA
  - Mar 19, 2026 KERMT molecular property prediction model Source
- Variational AI
  - Sep 23, 2025 Variational AI Enki generative small-molecule design collaboration Source
    Sep 23, 2025 Collaboration with Merck & Co. (MSD) applying Enki platform (official) Source
Roche

4 AI partners
- Dyno Therapeutics
  - Jan 13, 2025 Roche exercised option to license an AI-designed AAV vector for neurology Source
- Manifold Bio
  - Nov 3, 2025 Blood-brain barrier shuttle collaboration with $55M upfront, over $2B in milestones and tiered royalties Source
- NVIDIA
  - Mar 16, 2026 Genentech/Roche Lab-in-the-Loop AI drug discovery strategy Source
- Recursion
  - Aug 6, 2026 First neuroscience target delivered in Genentech collaboration Source
Takeda

4 AI partners
- Boltz
  - Jun 18, 2026 Collaboration with Takeda to deploy frontier models organization-wide Source
- Iambic Therapeutics
  - Feb 9, 2026 Iambic AI small-molecule design collaboration Source
- Insilico Medicine
  - Jul 7, 2026 Collaboration with Takeda using generative models to design drug candidates for promising targets Source
- Nabla Bio
  - Oct 14, 2025 Second Takeda collaboration on AI-designed protein therapeutics, with double-digit millions in upfront and research payments and headline potential payments over $1B Source
AstraZeneca

3 AI partners
- insitro
  - Oct 15, 2026 Strategic collaboration with AstraZeneca for AI-enabled discovery in MASH (metabolic dysfunction-associated steatohepatitis) and cardiomyopathies. insitro's post says it gets $40M upfront and is eligible for up to about $1.46B in milestones Source
    Oct 15, 2026 Strategic collaboration with AstraZeneca on AI-enabled MASH/metabolic discovery Source
- Owkin
  - May 13, 2026 Multi-year K Pro license and AI agent deal with AstraZeneca Source
- Turbine
  - Oct 9, 2025 New ADC collaboration with AstraZeneca using virtual disease models Source
Bayer

3 AI partners
- Cradle
  - Jan 16, 2026 Strategic collaboration with Bayer on generative AI antibody optimization Source
- Iambic Therapeutics
  - Jun 22, 2026 Iambic AI small-molecule discovery collaboration Source
- Recursion
  - Nov 9, 2023 Recursion AI-guided oncology research collaboration Source
Merck KGaA

3 AI partners
- imec
  - May 20, 2025 imec microphysiological-systems platform to generate AI training data Source
- PostEra
  - Sep 9, 2026 EMD Serono (Merck KGaA) acquired two PostEra fertility programs Source
- Valo Health
  - Nov 20, 2025 Collaboration with Merck KGaA in Parkinson's disease (official) Source
Novartis

3 AI partners
- Chai Discovery
  - Jul 13, 2026 Expanded collaboration with Novartis after a year-long technical engagement Source
- Isomorphic Labs
  - Feb 18, 2025 Expanded Novartis collaboration, doubling the number of research programs Source
- Relation Therapeutics
  - Dec 9, 2025 Collaboration with Novartis on drug targets for atopic diseases Source
Novo Nordisk

3 AI partners
- AWS
  - Aug 10, 2026 Strategic partnership with AWS to accelerate drug discovery with AI, making AWS its preferred cloud provider and strategic AI partner Source
    Aug 10, 2026 Novo Nordisk post announcing a strategic partnership with AWS to accelerate drug discovery through AI Source
- NVIDIA
  - Jun 23, 2025 Partnership with Novo Nordisk and Danish Centre for AI Innovation on Gefion for drug discovery Source
- OpenAI
  - Apr 14, 2026 OpenAI strategic partnership Source
Bristol Myers Squibb

2 AI partners
- Chai Discovery
  - Aug 20, 2026 Collaboration with Bristol Myers Squibb on AI antibody discovery Source
- Terray Therapeutics
  - Dec 3, 2025 Discovery milestone reached in multi-target small-molecule collaboration with BMS Source
Gilead

2 AI partners
- Tempus
  - Apr 9, 2026 Expanded multi-year oncology collaboration with Gilead Source
- Terray Therapeutics
  - Dec 17, 2024 Multi-target research collaboration on small-molecule therapies Source
Pfizer

2 AI partners
- Chai Discovery
  - Jun 4, 2026 Collaboration with Pfizer to deploy Chai-3 and a custom model built on Pfizer data Source
- PostEra
  - Jan 7, 2025 PostEra AI Lab expansion and ADC payload collaboration (Proton platform) Source
    Jan 7, 2025 Double expansion of AI Lab collaboration with Pfizer Source
Regeneron

2 AI partners
- TriNetX
  - Apr 2, 2026 TriNetX de-identified EHR access for research and AI training Source
- Truveta
  - Jan 13, 2025 Truveta Genome Project exome sequencing for AI-enabled research Source
Sanofi

2 AI partners
- Owkin
  - Jun 5, 2026 Multi-year collaboration with Sanofi to co-develop biopharma agents, with a five-year K Pro license Source
- Recursion
  - Oct 15, 2026 Sanofi partnership milestone and oversubscribed $200M offering Source
UCB

2 AI partners
- Aitia
  - Mar 15, 2023 Aitia Causal AI collaboration in Huntington's disease Source
- Microsoft
  - Feb 23, 2021 Microsoft AI collaboration for drug discovery and development Source
Vertex

2 AI partners
- AbCellera
  - Jul 29, 2026 Collaboration with Vertex on multispecific T-cell engagers for autoimmune disease Source
- Genomics plc
  - Jul 16, 2024 Genomics plc human-genetics ML collaboration Source

How to read the map

A partnership is one pharma company and one AI partner. A deal is one agreement between them. When several announcements, filings or posts report the same deal, or a later milestone in it, the deal counts once and every source is linked under it.
Sources are Pharma AI Tracker entries and verified company posts on X. Funding rounds, share offerings and general news are left out.
Every line on the map is drawn the same width. The company cards list each partnership's deals and the sources for each one.
Companies are ranked by number of AI partners, then by deals. Companies with a single sourced partnership are not shown.
Partners can be AI drug discovery companies, AI and cloud platforms, health data companies or research centers. Each one is on the map because its source names it as the pharma company's AI partner.
Company names link to their Pharma AI Tracker page, which records what each company says about its own AI work.

Spot an error or a missing source? Tell me and I'll fix it.